We have previously shown that enzastaurin inhibits the cell growth at 5 μM in mesothelioma cell lines.[16] Thus, it will be important to investigate enzastaurin’s mode of action in malignant mesothelioma to extend our understanding of PKC-β in carcinogenesis, functional association with VEGFR and to optimize the activity of enzastaurin in preclinical models. Here, PRKCB is linked to mesothelioma.